DSS, Inc.
New York Stock Exchange ArcaRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- DSS, Inc. operates as a multinational diversified holding company, actively engaging in a broad spectrum of industries across the globe. The company specializes in consumer packaging, offering a variety of custom folding cartons, mailers, photo sleeves, and advanced anti-counterfeiting solutions through its Premier Packaging subsidiary. In the biotechnology sector, through its Impact BioMedical entity, DSS invests in and acquires enterprises within the biohealth and biomedical domains. This includes advancing research and development for drug discovery, as well as strategies for the prevention, inhibition, and treatment of complex neurological, oncological, and immune-related conditions, alongside patented nutraceuticals and potential therapeutics. Recent corporate actions involved the successful spin-off of Impact BioMedical, Inc. in September 2024, designed to enhance shareholder value. The company also maintains a significant presence in direct marketing, distributing health and wellness products through digital channels and partner networks, exemplified by DSS PureAir's air and surface purification offerings. Within financial services, DSS focuses on commercial lending and strategically acquiring equity in various financial institutions, including commercial banks, bank holding companies, and non-banking licensed entities in diverse international markets. This segment operates via American Pacific Financial, providing commercial banking, investment banking, and asset management, while Sentinel Brokers Company, Inc., a subsidiary, functions as a FINRA-registered broker-dealer specializing in bond brokerage and equity market making. Furthermore, DSS is involved in securities and investment management, developing and acquiring assets in the trading and funds management arena, including real estate investment funds. This encompasses operating a real estate investment trust focused on acquiring healthcare facilities such as hospitals and acute or post-acute care centers, alongside initiatives for creating healthy living communities. The firm has also ventured into digital assets, including establishing an innovative marketplace for trading digital assets based on U.S. equity securities. A core component of DSS's operations lies in healthcare technology and digital transformation, where it serves as a leading provider of health information technology (HIT) solutions for federal, private, and public healthcare organizations. This involves delivering electronic documentation software, EHR solutions through Juno Health, and comprehensive systems integration, with a particular emphasis on supporting the Department of Veterans Affairs (VA) in modernizing its health IT infrastructure and improving patient care. The company also explores alternative energy solutions, having previously developed solar farms, solar battery banks, and residential energy creation and storage services. Originally incorporated in 1984, the company was known as Document Security Systems, Inc. before officially changing its name to DSS, Inc. in September 2021. DSS, Inc. maintains its corporate headquarters in North Palm Beach, Florida.
Company News
DSS, Inc. Launches DSS Robotics to Bring AI-Powered Automation to Enterprise Operations
DSS Shares Crash After Soaring. What the New Offering Means for Investors
DSS, Inc. Announces Decision Not to Proceed with Proposed Public Offering
DSS, Inc. Announces Launch of Proposed Public Offering
DSS, Inc. Withdraws Registration Statement
ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027
DSS, Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing
DSS, Inc. Letter to Shareholders
DSS, Inc. Announces Closing of $1.0 Million Underwritten Public Offering
DSS, Inc. Announces Pricing of $1.0 Million Underwritten Public Offering
DSS, Inc. Announces Launch of Proposed Public Offering
DSS, Inc. Reports Strong Q1 2025 Financial Performance, Setting the Stage for Strategic Growth
DSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining Portfolio for Strategic Growth
DSS, Inc. Issues Letter to Shareholders
DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value
AmericaFirst Funds Trust Announces Changes to Board of Trustees
DSS, Inc. Names Jason Grady as Interim Chief Executive Officer
Yugabyte Embraces ‘No Downtime, No Limits,’ as the Theme of the Upcoming Distributed SQL Summit Asia
Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose™ Technology Entitled "Low Glycemic Sugar Composition."
DSS, Inc. Chairman Chan Acquires 672,173 shares of DSS In Open Market